Reply to: "Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling"

Comment

Charles D Howell et al. J Hepatol. 2013 Apr.

. 2013 Apr;58(4):842-3.

doi: 10.1016/j.jhep.2012.12.004. Epub 2012 Dec 11.

No abstract available

Comment on

Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1.
Howell CD, Gorden A, Ryan KA, Thompson AJ, Ibrahim C, Fried M, Afdhal NH, McHutchison JG, Shianna KV, Goldstein DB, Shuldiner AR, Mitchell BD. Howell CD, et al. J Hepatol. 2012 Mar;56(3):557-63. doi: 10.1016/j.jhep.2011.10.004. Epub 2011 Oct 23. J Hepatol. 2012. PMID: 22027585 Free PMC article.
Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling.
Dahari H, Cotler SJ, Layden TJ, Perelson AS. Dahari H, et al. J Hepatol. 2013 Apr;58(4):840-2. doi: 10.1016/j.jhep.2012.08.029. Epub 2012 Dec 13. J Hepatol. 2013. PMID: 23246507 Free PMC article. No abstract available.